100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Exam (elaborations) NUR 601 Week 2 Polypharmacy Discussion $12.49   Add to cart

Exam (elaborations)

Exam (elaborations) NUR 601 Week 2 Polypharmacy Discussion

 5 views  0 purchase
  • Course
  • Institution

Week 2 Polypharmacy Discussion Polypharmacy is a common concern, especially in the elderly.

Preview 2 out of 7  pages

  • March 4, 2022
  • 7
  • 2021/2022
  • Exam (elaborations)
  • Questions & answers
avatar-seller
Week 2 Polypharmacy Discussion
Polypharmacy is a common concern, especially in the elderly.

 List the definitions of polypharmacy you encounter in your readings. There is more than one.

o Polypharmacy, the use of multiple pharmacies (in this case providers and self-
prescribers) is a public health concern. Multiple prescribers, use of over-the-counter
medications, and readily available supplements are all challenges of prescribing for older
adults ( Chamberlain College of Nursing, 2018).

o Polypharmacy, multiple providers and prescribers, adherence and cost, use of over-
the-counter medications, and readily available herbals and supplements are all the
challenges of prescribing for older adults (Terrery & Nicoteri, 2016).

o the use of multiple medicines, commonly referred to as polypharmacy is common in
the older population with multimorbidity, as one or more medicines may be used to treat
each condition (Masnoon, Skakib, & Caughey, 2017).

 Discuss three risk factors that can lead to polypharmacy. Explain the rationale for why each listed
item is a risk factor.
This is different than adverse drug reactions. ADRs can be a result of polypharmacy, and is
important, but ADRs are not a risk factor.
• Self-Medication. Rationale; Many patients buy their own prescribed medicine from the
chemist close to their location, and thus they are at risk of polypharmacy. Due to the
rising cost of medication patients are more likely to take medications they may have been
prescribed in the past leading to self- medication (Maher, Hanlon, & Hajjar, 2014).
• Chronic comorbidities. Rationale; instance a patient with hypertension, heart failure,
hyperlipidemia, obstructive sleep apnea, and diabetic is likely to be a subject to
polypharmacy. In which patients have multiple providers each of the providers may still
have paper charts or EMR’s in which are separate entities and do not share the
information with the patient’s other physicians regarding the visit to have continuity of
care resulting in polypharmacy (Maher, Hanlon, & Hajjar, 2014).
 Old age. Rationale; The elderly are at risk of polypharmacy since they may use both
herbal medicines and the modern medicines and also, they may have the cognitive
impairments that make them unable to make the right judgments on which drugs to take,
the right quantities and the right time (Maher, Hanlon, & Hajjar, 2014).

 Discuss three action steps that a provider can take to prevent polypharmacy.
o Reviewing of patient treatment sheet to prevent duplication of medication upon any transition
to any medical facility or even the chemist to avoid polypharmacy. The brown bag review is
having the patient bring in their medications to the visit review them and gather the medication or
have the medication history taken by the pharmacist (McGrath, Hajjar, Kumar, Hwang &
Salzman, 2017).

o Creating a follow-up plan. At the time of deprescribing a medication, develop a plan with the
patient for monitoring and assessment. Ensure that the patient understands which symptoms may
occur in the event of drug withdrawal and which symptoms may suggest the return of a condition
(McGrath, Hajjar, Kumar, Hwang & Salzman, 2017).




This study source was downloaded by 100000842670546 from CourseHero.com on 03-04-2022 12:50:24 GMT -06:00


https://www.coursehero.com/file/33235624/Week-2-Polypharmacy-Discussiondocx/

,  Talk to the patient about the deprescribing process, talk with the patient about the risks and
benefits of deprescribing, and prioritize which medications to address in the process. Prioritize
the medications by balancing patient preferences with available pharmacologic evidence
(McGrath, Hajjar, Kumar, Hwang & Salzman, 2017).

 Provide an example of how your clinical preceptors have addressed polypharmacy.
o Obtain pharmacist recommendations to reduce inappropriate prescribing and adverse
drug events
o use computerized alerts to reduce serious medication errors and help prevent adverse
drug events
o Review a patient's medications to reduce polypharmacy and inappropriate prescribing


References


Chamberlain College of Nursing. (2018) NR-601 Week 2 : Polypharmacy [Online lesson].Downers
Grove,IL. DeVry Education Group.

Maher, R. L., Hanlon, J. T., & Hajjar, E. R. (2014). Clinical Consequences of Polypharmacy in
Elderly. Expert Opinion on Drug Safety, 13(1), 10.1517/14740338.2013.827660.
http://doi.org/10.1517/14740338.2013.827660

Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A
systematic review of definitions. BMC Geriatrics, 17(1), 230. doi:10.1186/s12877-017-0621-2

McGrath, K., Hajjar, E. R., Kumar, C., Hwang, C., & Salzman, B. (2017). Deprescribing: A simple
method for reducing polypharmacy. The Journal Of Family Practice, 66(7), 436-445.

Terrery, C. L., & Nicoteri, J. A. L. (2016). The 2015 american geriatric society beers criteria: Implications
for nurse practitioners. The Journal for Nurse Practitioners, 12(3), 192-200.
doi:http://dx.doi.org.chamberlainuniversity.idm.oclc.org/10.1016/j.nurpra.2015.11




Hi Sara,
Wonderful work with the polypharmacy discussion!
As we go through each week, I'll be posting additional questions for discussion in bold-
faced font. For participation purposes (to achieve full points), the bold-faced font
questions will need to be answered in a scholarly manner (with evidence-based
support).
A question for further discussion... next week, we'll be discussing geriatric
assessment tools more in depth. (i.e. PHQ-9 questionnaire for depression
assessment). What geriatric assessment tool would be beneficial to help
minimize or prevent polypharmacy?




This study source was downloaded by 100000842670546 from CourseHero.com on 03-04-2022 12:50:24 GMT -06:00


https://www.coursehero.com/file/33235624/Week-2-Polypharmacy-Discussiondocx/

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Valleria17. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $12.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

75632 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$12.49
  • (0)
  Add to cart